WO2023208173A1 - Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors - Google Patents

Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors Download PDF

Info

Publication number
WO2023208173A1
WO2023208173A1 PCT/CN2023/091483 CN2023091483W WO2023208173A1 WO 2023208173 A1 WO2023208173 A1 WO 2023208173A1 CN 2023091483 W CN2023091483 W CN 2023091483W WO 2023208173 A1 WO2023208173 A1 WO 2023208173A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkynyl
alkenyl
heterocyclyl
heteroaryl
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/091483
Other languages
English (en)
French (fr)
Inventor
Jing Li
Wenqing Xu
Zhiwei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2024563509A priority Critical patent/JP2025516213A/ja
Priority to KR1020247039643A priority patent/KR20250004890A/ko
Priority to EP23795605.7A priority patent/EP4514791A4/en
Priority to AU2023260284A priority patent/AU2023260284A1/en
Priority to CN202380036165.1A priority patent/CN119095840A/zh
Priority to IL316556A priority patent/IL316556A/en
Priority to CA3256792A priority patent/CA3256792A1/en
Priority to CN202510407101.9A priority patent/CN120441555A/zh
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of WO2023208173A1 publication Critical patent/WO2023208173A1/en
Priority to US18/623,847 priority patent/US20240300937A1/en
Priority to MX2024013266A priority patent/MX2024013266A/es
Priority to CONC2024/0014595A priority patent/CO2024014595A2/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Definitions

  • This disclosure provides compounds containing 6- (pyrimidin-4-yl) quinoline structure, the use thereof for selectively inhibiting the activity of cyclin-dependent kinase 4 (CDK4) , and pharmaceutical compositions comprising the compounds as the treatment of various diseases including cancer.
  • CDK4 cyclin-dependent kinase 4
  • Human kinase is a large group of enzymes that add phosphate groups (PO 4 3- ) to other molecules in human body [1. FASEB J. 1995 May; 9 (8) : 576-96.2. Enzyme Res. 2011; 2011: 794089. ] . There are more than 500 kinase-encoding genes that exist in the human genome and their substrates including proteins, lipids, and nucleic acids [3. Cell Signal. 2004 Sep; 16 (9) : 983-9.4. Cell. 2017 Aug 10; 170 (4) : 605-635. ] . Kinase mis-regulation is identified in many diseases including cancer, autoimmunity, neurological disorders, diabetes and cardiovascular disease.
  • the mutated kinases can become constitutively active and thus cause diverse cellular anomalies, leading to cancer initiation or growth.
  • Using small molecular inhibitors to inhibit kinase activity is proved to be a successful method to treat cancer and other disease [5. Expert Rev Anticancer Ther. 2018 Dec; 18 (12) : 1249-1270. ] .
  • Up to now, there are more than 70 kinase inhibitors have been approved by FDA, EMA or CDE as drugs [6. Nat Rev Drug Discov. 2018 May; 17 (5) : 353-377. ] .
  • Protein kinase family takes a majority fraction of the kinase superfamily.
  • protein kinases can phosphorylate the amino acids including serine, threonine, tyrosine and histidine.
  • Protein kinases play a major role in cellular activation processes, through reversible phosphorylation and dephosphorylation of proteins, by the antagonistic action of kinases and phosphatases, is an important component of cell signaling because the phosphorylated and unphosphorylated states of the target protein can have different levels of activity.
  • Different protein kinases including EGFR, BTK, ALK, JAK, PI3K and CDK are proved to be good targets for cancer drug development.
  • cyclins are among the most important core cell cycle regulators. There are four basic cyclin types found in humans including G1 cyclins, G1/Scyclins, S cyclins and M cyclins. To drive the cell cycle forward, a cyclin must activate or inactivate many target proteins inside of the cell. And these cyclins drive the events of the cell cycle majorly by partnering with a family of enzymes called the cyclin-dependent kinases (CDKs) .
  • CDKs cyclin-dependent kinases
  • CDK kinase itself is inactive, but binding with a cyclin can activate it, making the CDK/cyclin complex a functional holoenzyme and allowing it to modify target proteins [11. Orphanet J Rare Dis. 2020 Aug 6; 15 (1) : 203.12. J Mol Biol. 1999 Apr 16; 287 (5) : 821-8. ] .
  • CDKs serine/threonine protein kinases that form a CDK and CDK-like branch of the CMGC subfamily of the human kinome; of these, 21 are classified as CDKs.
  • CDK1, CDK2, CDK4 and CDK6 are considered as the direct modulator of cell cycle majorly by phosphorylating and inactivating retinoblastoma protein and releasing E2F transcription factors, and E2F downstream pathway is critical in regulating the initiation of DNA replication.
  • CDK4/6 is essential for G1 early initiation and G1/Stransition.
  • CDK4/6 related pathway is commonly disregulated in many different cancer types such as breast cancer, lung cancer and pancreatic cancer.
  • CDK4/6 inhibitors including palbociclib, ribociclib, abemaciclib and trilaciclib which have been approved by FDA or CDE to be used as either single agent or combo with endocrine therapy to treat HR+, Her2-breast cancer.
  • This approach shows good efficacy in the clinic while hematopoietic toxicity like neutropenia and leukopenia which may limit the clinical application of CDK4/6 dual inhibitors.
  • emerging data indicating that inhibition of CDK6/Cyclin D3 may cause the clinical observed hematologic toxicity [15. Cell. 2004 Aug 20;118 (4) : 493-504.16.
  • CDK4/Cyclin D1 is the oncogenic driver in different cancers [17. Nat Commun. 2019 Dec 20; 10 (1) : 5817.18.18. Cancer Cell. 2006 Jan; 9 (1) : 23-32. ] .
  • Development of a selective CDK4 selective inhibitor might show improved efficacy, mitigated hematologic toxicity and expanded clinical usage in many cancers including but not limited to breast cancer, lung cancer, pancreatic cancer, prostate cancer, bone cancer, liver cancer and endometrial cancer.
  • the inventors of the instant invention found the selective CDK4 inhibitor compounds with high CDK4 selectivity all other kinases including CDK6, which potentially lead to better efficacy, improved toxicity profile and potential to overcome resistance mechanisms, and the like.
  • One objective of the present invention is to provide compounds and derivatives which function to act as CDK4 inhibitors, and methods of preparation and uses thereof.
  • ring CyA is a 3-to 8-membered ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen, oxygen, or optionally oxidized sulfur as ring member (s) ; said ring is optionally substituted with at least one substituent R 10 ;
  • n 0, 1, 2, 3, 4 or 5;
  • R 1 is H, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, haloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR 1a , -COR 1a , -CO 2 R 1a , -CONR 1a R 1b , -NR 1a R 1b , -NR 1a COR 1b , -NR 1a CO 2 R 1b or -NR 1a CONR 1b R 1c ; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 1d ;
  • R 1a , R 1b and R 1c are each independently selected from hydrogen, -C 1-8 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 1f ;
  • R 1d and R 1f are each independently selected from hydrogen, halogen, hydroxy, -C 1-8 alkyl, -haloC 1- 8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen
  • R 2 is hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -OR 2a , -SO 2 R 2a , -SO 2 NR 2a R 2b , -COR 2a , -CO 2 R 2a , -CONR 2a R 2b , -NR 2a R 2b , -NR 2a COR 2b , -NR 2a CO 2 R 2b , -NR 2a CONR 2b R 2c , or –NR 2a SO 2 R 2b ; wherein each of said -C 1-8 alkyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 2d
  • R 2a , R 2b and R 2c are each independently selected from hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 2f ; or
  • R 2a and R 2b , (R 2b and R 2c ) or (R 2a and R 2c ) together with the atom (s) to which they are attached, form a 3-to 12-membered ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen, oxygen, or optionally oxidized sulfur as ring member (s) , said ring is optionally substituted with at least one substituent R 2f ;
  • R 2d and R 2f are each independently selected from hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -OR 2g , -SO 2 R 2g , -SO 2 NR 2g R 2h , -COR 2g , -CO 2 R 2g , -CONR 2g R 2h , -NO 2 , -NR 2g R 2h , -NR 2g COR 2h , -NR 2g CO 2 R 2h , -NR 2g CONR 2h R 2i , or –NR 2g SO 2 R 2h ; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl
  • R 2g , R 2h and R 2i are each independently selected from hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -haloC 1- 8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or
  • R 3A and R 3B are each independently hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or -CN; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 3c ; or
  • R 3c is each independently selected from hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -OR 3d , -SO 2 R 3d , -SO 2 NR 3d R 3e , -COR 3d , -CO 2 R 3d , -CONR 3d R 3e , -NO 2 , -NR 3d R 3e , -NR 3d COR 3e , -NR 3d CO 2 R 3e , -NR 3d CONR 3e R 3f , or –NR 3d SO 2 R 3e ; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substitute
  • R 3d , R 3e and R 3f are each independently selected from hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -haloC 1- 8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or
  • R 4 is hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl or heterocyclyl; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl or heterocyclyl is optionally substituted with at least one substituent R 4a ;
  • R 4a is each independently selected from hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -OR 4b , -SO 2 R 4b , -SO 2 NR 4b R 4c , -COR 4b , -CO 2 R 4b , -CONR 4b R 4c , -NO 2 , -NR 4b R 4c , -NR 4b COR 4c , -NR 4b CO 2 R 4c , -NR 4b CONR 4c R 4d or –NR 4b SO 2 R 4c ; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with
  • R 4b , R 4c and R 4d are each independently selected from hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -haloC 1- 8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from H, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR 5a , -COR 5a , -CO 2 R 5a , -CONR 5a R 5b , -NR 5a R 5b , -NR 5a COR 5b , -NR 5a CO 2 R 5b or -NR 5a CONR 5b R 5c ; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 5d ;
  • R 5a , R 5b and R 5c are each independently selected from hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 5f ;
  • R 5d and R 5f are each independently selected from hydrogen, halogen, hydroxy, -C 1-8 alkyl, -haloC 1- 8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen
  • R 10 is selected from H, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR 10a , -COR 10a , -CO 2 R 10a , -CONR 10a R 10b , -NR 10a R 10b , -NR 10a COR 10b , -NR 10a CO 2 R 10b or -NR 10a CONR 10b R 10c ; wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 10d ;
  • R 10a , R 10b and R 10c are each independently selected from hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with at least one substituent R 10f ;
  • R 10d and R 10f are each independently selected from hydrogen, halogen, hydroxy, -C 1-8 alkyl, -haloC 1- 8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen
  • R 11 is selected from H, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl; wherein each of said -C 1-8 alkyl, -C 2- 8 alkenyl or -C 2-8 alkynyl is optionally substituted with at least one substituent R 11a ;
  • R 11a is selected from hydrogen, halogen, hydroxy, -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2- 8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, -
  • Aspect 2 The compound of Aspect 1, wherein the compound is selected from formula (IIa) , (IIb) , (IIc) , (IId) or (IIe) :
  • R 1 , R 2 , R 3A , R 3B , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , m and n are each defined as Aspect 1;
  • the compound is selected from formula (IIf) , (IIg) , (IIh) or (IIi) :
  • R 1 , R 2 , R 3A , R 3B , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and n are each defined as Aspect 1;
  • the compound is selected from formula (IIj) , (IIk) , (IIl) or (IIm) :
  • R 1 , R 2 , R 3A , R 3B , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and n are each defined as Aspect 1;
  • the compound is selected from formula (IIn) , (IIo) , (IIp) or (IIq) :
  • R 1 , R 2 , R 3A , R 3B , R 5 , R 6 , R 7 , R 8 , R 10 , m and n are each defined as Aspect 1.
  • Aspect 3 The compound of anyone of the preceding Aspects, wherein ring CyA is a 3-, 4-, 5-, 6-, 7-or 8-membered ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen, oxygen, or optionally oxidized sulfur as ring member (s) ; said ring is optionally substituted with 0, 1, 2, 3, 4 or 5 R 10 ; said ring is a saturated or unsaturated ring;
  • CyA is a 3-, 4-, 5-, 6-, 7-or 8-membered saturated ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen, oxygen, or optionally oxidized sulfur as ring member (s) ; said ring is optionally substituted with 0, 1, 2 or 3 R 10 ;
  • CyA is a 5-, 6-or 7-membered saturated ring, said ring comprising 1 or 2 heteroatom (s) independently selected from nitrogen or oxygen as ring member (s) ; said ring is optionally substituted with 0, 1, 2 or 3 R 10 ;
  • CyA is a ring selected from tetrahydrofuranyl or tetrahydropyranyl; said ring is optionally substituted with 0, 1, 2 or 3 R 10 .
  • Aspect 4 The compound of anyone of the preceding Aspects, wherein ring CyA is
  • CyA is more preferably, CyA is even more preferably, CyA is
  • Aspect 5 The compound of anyone of the preceding Aspects, wherein R 10 is selected from -H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, -CN, -OR 10a , -COR 10a , -CO 2 R 10a , -CONR 10a R 10b , -NR 10a R 10b , -NR 10a COR 10b , -NR 10a CO 2 R 10b or -NR 10a CONR 10b R 10c ; wherein each
  • R 10a , R 10b and R 10c are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • R 10d and R 10f are each independently selected from hydrogen, -F, -Cl, -Br, -I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -haloC 1-8 alkyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, phenyl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said methyl, ethyl, propy
  • R 10 is selected from -H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, -CN, -OH or -NH 2 ;
  • R 10 is -OH.
  • Aspect 7 The compound of anyone of the preceding Aspects, wherein R 1 is H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, haloalkyl, heterocyclyl, -CN, -OR 1a , -COR 1a , -CO 2 R 1a , -CONR 1a R 1b , -NR 1a R 1b , -NR 1a COR 1b , -NR 1a CO 2 R 1b or -NR 1a CONR 1b R 1c ; wherein each of said methyl,
  • R 1a , R 1b and R 1c are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl is optionally substituted with at least one substituent R 1f ;
  • R 1d and R 1f are each independently selected from hydrogen, -F, -Cl, -Br, -I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -haloC 1-8 alkyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, phenyl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said methyl, ethyl, propy
  • R 1 is H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, haloalkyl, heterocyclyl or -CN;
  • R 1 is H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl or tert-butyl;
  • R 1 is
  • Aspect 8 The compound of anyone of the preceding Aspects, wherein R 2 is hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, oxo, -CN, -OR 2a , -SO 2 R 2a , -SO 2 NR 2a R 2b , -COR 2a , -CO 2 R 2a , -CONR 2a R 2b , -NR 2a R 2b , -NR 2a COR 2b , -NR 2a
  • R 2a , R 2b and R 2c are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • R 2a and R 2b , (R 2b and R 2c ) or (R 2a and R 2c ) together with the atom (s) to which they are attached, form a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-or 12-membered ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen, oxygen, or optionally oxidized sulfur as ring member (s) , said ring is optionally substituted with at least one substituent R 2f ;
  • R 2d and R 2f are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, oxo, -CN, -OR 2g , -SO 2 R 2g , -SO 2 NR 2g R 2h , -COR 2g , -CO 2 R 2g , -CONR 2g R 2h , -NO 2 , -NR 2g R 2h , -NR 2g COR 2h , -NR 2g CO 2
  • R 2g , R 2h and R 2i are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • Aspect 9 The compound of anyone of the preceding Aspects, wherein R 2 is hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, oxazepanyl, oxetanyl, azetidinyl, oxa-azaspiro [4.4] nonanyl, hexahydro-1H-furo [3, 4-c]pyrrolyl, octahydropyrrolo [3, 4-c] pyrrolyl, di
  • R 2a and R 2b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, oxazepanyl, oxetanyl, azetidinyl, oxa-azaspiro [4.4] nonanyl, hexahydro-1H-furo [3, 4-c] pyrrolyl, octahydropyrrolo [3, 4-c] pyrrolyl, diazaspiro
  • R 2a and R 2b , (R 2b and R 2c ) or (R 2a and R 2c ) together with the atom (s) to which they are attached, form a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-or 12-membered ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen or oxygen as ring member (s) , said ring is optionally substituted with at least one substituent R 2f ;
  • R 2d and R 2f are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, oxazepanyl, oxetanyl, azetidinyl, oxa-azaspiro [4.4] nonanyl, hexahydro-1H-furo [3, 4-c]pyrrolyl, octahydropyrrol
  • R 2g , R 2h and R 2i are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • Aspect 10 The compound of anyone of the preceding Aspects, wherein R 2 is hydrogen, methyl, ethyl, propyl, butyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, oxazepanyl, oxetanyl, azetidinyl, oxa-azaspiro [4.4] nonanyl, hexahydro-1H-furo [3, 4-c] pyrrolyl, octahydropyrrolo [3, 4-c] pyrrolyl, diazaspiro [4.5] decanyl, oxa-azaspiro [4.5] decanyl, azabicyclo [3.3.1] nonanyl, piperidinyl, piperazinyl, oxa-azaspiro [2.5] octanyl, oxa-azabicyclo [3.1.1]
  • R 2a and R 2b are each independently selected from hydrogen, methyl, ethyl, propyl (n-propyl or iso-propyl) , butyl (n-butyl, sec-butyl, iso-butyl or tert-butyl) , pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, oxazepanyl, oxetanyl, azetidinyl, oxa-azaspiro [4.4] nonanyl, hexahydro-1H-furo [3, 4-c] pyrrolyl, octahydropyrrolo [3, 4-c] pyrrolyl, diazaspiro [4.5] decanyl, oxa-
  • R 2a and R 2b , (R 2b and R 2c ) or (R 2a and R 2c ) together with the atom (s) to which they are attached, form a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-or 12-membered ring, said ring comprising 0, 1 or 2 heteroatom (s) independently selected from nitrogen or oxygen as ring member (s) , said ring is optionally substituted with at least one substituent R 2f ;
  • R 2d and R 2f are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, -CF 3 , -CF 2 H, -CFH 2 , -CH 2 CF 3 , -CF 2 CH 3 , -CH 2 OH, -CH (CH 3 ) OH, -C (CH 3 ) 2 OH, -CH 2 CH 2 OH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, oxazepanyl, oxetanyl, azetidinyl, oxa-azaspiro [4.4] nonanyl, hexahydro-1H-furo [
  • Aspect 11 The compound of anyone of the preceding Aspects, wherein R 2 is -H, -Me, -OMe, -OH, -NH 2 , -NHCH 3 , -N (CH 3 ) 2 , -NHCH (CH 3 ) 2 , -NHC (CH 3 ) 3 , -NHCOCH 3 ,
  • R 3A and R 3B are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl or -CN; wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl,
  • R 3c is each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, oxo, -CN, -OR 3d , -SO 2 R 3d , -SO 2 NR 3d R 3e , -COR 3d , -CO 2 R 3d , -CONR 3d R 3e , -NO 2 , -NR 3d R 3e , -NR 3d COR 3e , -NR 3d CO 2 R 3e
  • R 3d , R 3e and R 3f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • R 3A and R 3B are each independently hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl or -CN; or
  • R 3c is each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, oxo, -CN, -OR 3d , -COR 3d , -CO 2 R 3d , -CONR 3d R 3e , -NO 2 , -NR 3d R 3e , -NR 3d COR 3e or -SO 2 R 3d ; wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cycl
  • R 3d and R 3e are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent -F, -Cl, -Br, -I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, h
  • R 3A and R 3B are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl; or
  • Aspect 14 The compound of anyone of the preceding Aspects, wherein the moiety is -Me, -Et,
  • Aspect 15 The compound of anyone of the preceding Aspects, wherein R 4 is hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or heterocyclyl; wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohept
  • R 4a is each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, oxo, -CN, -OR 4b , -SO 2 R 4b , -SO 2 NR 4b R 4c , -COR 4b , -CO 2 R 4b , -CONR 4b R 4c , -NO 2 , -NR 4b R 4c , -NR 4b COR 4c , -NR 4b CO 2 R 4c
  • R 4b , R 4c and R 4d are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • R 4 is hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or heterocyclyl;
  • R 4 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl iso-butyl tert-butyl
  • Aspect 16 The compound of anyone of the preceding Aspects, wherein R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, -CN, -OR 5a , -COR 5a , -CO 2 R 5a , -CONR 5a R 5b , -NR 5a R 5b , -NR 5a COR 5b , -NR 5a CO 2 R 5b or -
  • R 5a , R 5b and R 5c are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl, wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
  • R 5d and R 5f are each independently selected from hydrogen, -F, -Cl, -Br, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -haloC 1-8 alkyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, phenyl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said methyl, ethyl, propyl, buty
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, -CN, -OR 5a , -COR 5a , -CO 2 R 5a , -CONR 5a R 5b , -NR 5a R 5b , -NR 5a COR 5b , -NR 5a CO 2 R 5b or -NR 5a CONR 5b R 5c ;
  • R 5a , R 5b and R 5c are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl or heteroaryl;
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, heterocyclyl, phenyl, heteroaryl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -CN.
  • Aspect 17 The compound of anyone of the preceding Aspects, wherein R 5 , R 6 and R 7 are each independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; and/or
  • R 8 is selected from -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, hepthoxy, octoxy, -CN; and/or
  • R 9 is selected from H
  • R 5 , R 6 and R 7 are each independently selected from H, -F, -Cl, methyl, ethyl, propyl, butyl; and/or
  • R 8 is selected from -F, -Cl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, propoxy, butoxy, -CN; and/or
  • R 9 is selected from H.
  • Aspect 18 The compound of anyone of the preceding Aspects, wherein R 11 is selected from H, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl or -C 2-8 alkynyl; wherein each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl or -C 2-8 alkynyl is optionally substituted with at least one substituent R 11a ;
  • R 11a is selected from hydrogen, halogen, hydroxy, -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2- 8 alkenyl, -C 2-8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl, wherein each of said -C 1-8 alkyl, -haloC 1-8 alkyl, -C 1-8 alkoxy, -C 2-8 alkenyl, -C 2- 8 alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, haloheterocyclyl, aryl, haloaryl, heteroaryl or haloheteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, -
  • R 11 is selected from H, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2- 8 alkenyl or -C 2-8 alkynyl;
  • R 11 is selected from H, methyl, ethyl, propyl, butyl;
  • R 11 is H.
  • Aspect 19 The compound of anyone of the preceding Aspects, wherein the compound is selected from
  • a pharmaceutical composition comprising a compound of any one of Aspects 1-19 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, together with a pharmaceutically acceptable excipient.
  • Aspect 21 A method of decreasing CDK4 activity by inhibition, which comprises administering to an individual the compound according to any one of Aspects 1-19, or a pharmaceutically acceptable salt thereof, including the compound of formula (I) or the specific compounds exemplified herein.
  • Aspect 22 The method of Aspect 21, wherein the disease is selected from cancer, preferred breast cancer, lung cancer, pancreatic cancer, prostate cancer, bone cancer, liver cancer and endometrial cancer .
  • Aspect 23 Use of a compound of any one of Aspects 1-19 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof in the preparation of a medicament for treating a disease that can be affected by CDK4 modulation.
  • Aspect 24 The use of Aspect 23, wherein the disease is cancer, preferred breast cancer, lung cancer, pancreatic cancer, prostate cancer, bone cancer, liver cancer and endometrial cancer.
  • Aspect 25 A method of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of the compound any one of Aspects 1-19, or a pharmaceutically acceptable salt thereof as a CDK4kinase inhibitor, wherein the disease or disorder is associated with inhibition of CDK4.
  • Aspect 26 The method of Aspect 25, wherein the disease is selected from cancer, preferred breast cancer, lung cancer, pancreatic cancer, prostate cancer, bone cancer, liver cancer and endometrial cancer.
  • alkyl includes a hydrocarbon group selected from linear and branched, saturated hydrocarbon groups comprising from 1 to 18, such as from 1 to 12, further such as from 1 to 10, more further such as from 1 to 8, or from 1 to 6, or from 1 to 4, carbon atoms.
  • alkyl groups comprising from 1 to 6 carbon atoms include, but not limited to, methyl, ethyl, 1-propyl or n-propyl ( “n-Pr” ) , 2-propyl or isopropyl ( “i-Pr” ) , 1-butyl or n-butyl ( “n-Bu” ) , 2-methyl-1-propyl or isobutyl ( “i-Bu” ) , 1-methylpropyl or s-butyl ( “s-Bu” ) , 1, 1-dimethylethyl or t-butyl ( “t-Bu” ) , 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-penty
  • propyl includes 1-propyl or n-propyl ( “n-Pr” ) , 2-propyl or isopropyl ( “i-Pr” ) .
  • butyl includes 1-butyl or n-butyl ( “n-Bu” ) , 2-methyl-1-propyl or isobutyl ( “i-Bu” ) , 1-methylpropyl or s-butyl ( “s-Bu” ) , 1, 1-dimethylethyl or t-butyl ( “t-Bu” ) .
  • pentyl includes 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl.
  • hexyl includes 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2, 3-dimethyl-2-butyl and 3, 3-dimethyl-2-butyl.
  • alkylene refers to a divalent alkyl group by removing two hydrogen from alkane.
  • Alkylene includes but not limited to methylene, ethylene, propylene, and so on.
  • halogen includes fluoro (F) , chloro (Cl) , bromo (Br) and iodo (I) .
  • alkenyl group e.g., C 2-6 alkenyl
  • examples of the alkenyl group, e.g., C 2-6 alkenyl include, but not limited to ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1, 3-dienyl, 2-methylbuta-1, 3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1, 3-dienyl groups.
  • alkenylene refers to a divalent alkenyl group by removing two hydrogen from alkene.
  • Alkenylene includes but not limited to, vinylidene, butenylene, and so on.
  • alkynyl includes a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C ⁇ C triple bond and from 2 to 18, such as 2 to 8, further such as from 2 to 6, carbon atoms.
  • alkynyl group e.g., C 2-6 alkynyl
  • alkynylene refers to a divalent alkynyl group by removing two hydrogen from alkyne.
  • Alkenylene includes but not limited to ethynylene and so on.
  • cycloalkyl includes a hydrocarbon group selected from saturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups including fused, bridged or spiro cycloalkyl.
  • the cycloalkyl group may comprise from 3 to 12, such as from 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms.
  • the cycloalkyl group may be selected from monocyclic group comprising from 3 to 12, such as from 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms.
  • Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups.
  • examples of the saturated monocyclic cycloalkyl group include, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl is a monocyclic ring comprising 3 to 6 carbon atoms (abbreviated as C 3-6 cycloalkyl) , including but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • bicyclic cycloalkyl groups include those having from 7 to 12 ring atoms arranged as a fused bicyclic ring selected from [4, 4] , [4, 5] , [5, 5] , [5, 6] and [6, 6] ring systems, or as a bridged bicyclic ring selected from bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, and bicyclo [3.2.2] nonane.
  • bicyclic cycloalkyl groups include those arranged as a bicyclic ring selected from [5, 6] and [6, 6] ring systems.
  • spiro cycloalkyl includes a cyclic structure which contains carbon atoms and is formed by at least two rings sharing one atom.
  • fused cycloalkyl includes a bicyclic cycloalkyl group as defined herein which is saturated and is formed by two or more rings sharing two adjacent atoms.
  • bridged cycloalkyl includes a cyclic structure which contains carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other.
  • 7 to 10 membered bridged cycloalkyl includes a cyclic structure which contains 7 to 12 carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other.
  • fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl include but are not limited to bicyclo [1.1.0] butyl, bicyclo [2.1.0] pentyl, bicyclo [3.1.0] hexyl, bicyclo [4.1.0] heptyl, bicyclo [3.3.0] octyl, bicyclo [4.2.0] octyl, decalin, as well as benzo 3 to 8 membered cycloalkyl, benzo C 4-6 cycloalkenyl, 2, 3-dihydro-1H-indenyl, 1H-indenyl, 1, 2, 3, 4-tetralyl, 1, 4-dihydronaphthyl, etc.
  • Preferred embodiments are 8 to 9 membered fused rings, which refer to cyclic structures containing 8 to 9 ring atoms within the above examples.
  • aryl used alone or in combination with other terms includes a group selected from:
  • bicyclic ring systems such as 7 to 12 membered bicyclic ring systems, wherein at least one ring is carbocyclic and aromatic, e.g., naphthyl and indanyl; and,
  • tricyclic ring systems such as 10 to 15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, e.g., fluorenyl.
  • a monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C 5-10 aryl) .
  • Examples of a monocyclic or bicyclic aromatic hydrocarbon ring includes, but not limited to, phenyl, naphth-1-yl, naphth-2-yl, anthracenyl, phenanthrenyl, and the like.
  • the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or phenyl ring.
  • the aromatic hydrocarbon ring is a phenyl ring.
  • bicyclic fused aryl includes a bicyclic aryl ring as defined herein.
  • the typical bicyclic fused aryl is naphthalene.
  • heteroaryl includes a group selected from:
  • - 7-to 12-membered bicyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and
  • - 11-to 14-membered tricyclic rings comprising at least one heteroatom, for example, from 1 to 4, or in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring (s) of the heteroaryl group can be oxidized to form N-oxides.
  • bicyclic fused heteroaryl includes a 7-to 12-membered, preferably 7-to 10-membered, more preferably 9-or 10-membered fused bicyclic heteroaryl ring as defined herein.
  • a bicyclic fused heteroaryl is 5-membered/5-membered, 5-membered/6-membered, 6-membered/6-membered, or 6-membered/7-membered bicyclic. The group can be attached to the remainder of the molecule through either ring.
  • Heterocyclyl , “heterocycle” or “heterocyclic” are interchangeable and include a non-aromatic heterocyclyl group comprising one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, with the remaining ring members being carbon, including monocyclic, fused, bridged, and spiro ring, i.e., containing monocyclic heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, and fused heterocyclic groups.
  • At least one substituent includes, for example, from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents, provided that the theory of valence is met.
  • at least one substituent F disclosed herein includes from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents F.
  • divalent refers to a linking group capable of forming covalent bonds with two other moieties.
  • adivalent cycloalkyl group refers to a cycloalkyl group obtained by removing two hydrogen from the corresponding cycloalkane to form a linking group.
  • divalent aryl group refers to a cycloalkyl group obtained by removing two hydrogen from the corresponding cycloalkane to form a linking group.
  • divalent heterocyclyl group or “divalent heteroaryl group” should be understood in a similar manner.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another. Where the compounds disclosed herein possess two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds disclosed herein and/or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
  • substituents found on such ring system may adopt cis and trans formations.
  • Cis formation means that both substituents are found on the upper side of the 2 substituent placements on the carbon, while trans would mean that they were on opposing sides.
  • the di-substituted cyclic ring system may be cyclohexyl or cyclobutyl ring.
  • reaction products from one another and/or from starting materials.
  • the desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art.
  • separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography.
  • Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed ( "SMB” ) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
  • SMB simulated moving bed
  • Diastereomers refer to stereoisomers of a compound with two or more chiral centers but which are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride) , separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride
  • Enantiomers can also be separated by use of a chiral HPLC column.
  • a single stereoisomer e.g., a substantially pure enantiomer
  • Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. See: Wainer, Irving W., Ed. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.
  • keto and enol forms are also intended to be included where applicable.
  • Prodrug refers to a derivative of an active agent that requires a transformation within the body to release the active agent. In some embodiments, the transformation is an enzymatic transformation. Prodrugs are frequently, although not necessarily, pharmacologically inactive until converted to the active agent.
  • “Pharmaceutically acceptable salts” refer to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a pharmaceutically acceptable salt may be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting the free base function with a suitable organic acid or by reacting the acidic group with a suitable base.
  • the term also includes salts of the stereoisomers (such as enantiomers and/or diastereomers) , tautomers and prodrugs of the compound of the invention.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • administration when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid.
  • Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
  • administration and “treatment” also means in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell.
  • subject herein includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, and rabbit) and most preferably a human.
  • an effective amount refers to an amount of the active ingredient, such as compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom.
  • therapeutically effective amount can vary with the compound, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments.
  • “therapeutically effective amount” is an amount of at least one compound and/or at least one stereoisomer, tautomer or prodrug thereof, and/or at least one pharmaceutically acceptable salt thereof disclosed herein effective to “treat” as defined herein, a disease or disorder in a subject.
  • the term “therapeutically effective amount” refers to the total amount of the combination objects for the effective treatment of a disease, a disorder or a condition.
  • disease refers to any disease, discomfort, illness, symptoms or indications, and can be interchangeable with the term “disorder” or “condition” .
  • C n-m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C 1-8 , C 1-6 , and the like.
  • Compounds disclosed herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
  • the reaction for preparing compounds disclosed herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials, the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the boiling temperature of solvent.
  • a given reaction can be carried out in one solvent or mixture of solvents.
  • Reactions can be monitored according to any suitable method known in the art, such as NMR, UV, HPLC, LC-MS and TLC.
  • Compounds can be purified by a variety of methods, including HPLC and normal phase silica chromatography.
  • Chiral analytic HPLC was used for the retention time analysis of different chiral examples, the conditions were divided into the methods as below according to the column, mobile phase, solvent ration used.
  • compounds of Formulas (I) , (II) , (III) , or (IV) can be formed as shown in Scheme I.
  • the compound (i) can react with halogenated pyrimidine under palladium catalyzed reaction condition or base mediated coupling condition to give compound (ii) that can couple with amine to give compound (iii) , reduction and halogenation of compound (iii) give compound (iv) which can be used for coupling to give compound (v) .
  • compounds of Formulas (I) , (II) , (AIII) , (III) , (AIV) or (IV) can be formed as shown in Scheme II.
  • the compound (i) can react with halogenated pyrimidine under
  • Example 1 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropyl-N-methylquinoline-3-carboxamide
  • Step 1 ethyl 6-chloro-4-isopropylquinoline-3-carboxylate
  • Step 2 ethyl 4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3-carboxylate
  • Step 3 ethyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 4 ethyl 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4- isopropylquinoline-3-carboxylate
  • Step 5 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4- isopropylquinoline-3-carboxylic acid
  • Step 6 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4- isopropyl-N-methylquinoline-3-carboxamide
  • Step 4 4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline
  • Step 5 6- (2, 5-dichloropyrimidin-4-yl) -4-isopropylquinoline
  • Step 6 (3S, 4R) -4- ( (5-chloro-4- (4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H- pyran-3-ol
  • Step 2 6-chloro-2-methyl-4- (prop-1-en-2-yl) quinoline
  • Step 4 4-isopropyl-2-methyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline
  • Step 5 6- (2, 5-dichloropyrimidin-4-yl) -4-isopropyl-2-methylquinoline
  • Step 6 (3S, 4R) -4- ( (5-chloro-4- (4-isopropyl-2-methylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • the residue was purified by prep-HPLC under the following conditions: column, XBridge Shield RP18 OBD Column, 30 x 150 mm, 5 um; mobile phase, acetonitrile in water (with 10 mmol/L NH 4 HCO 3 and 0.1%NH 4 OH) , 31%to 61 %gradient in 9 min; detector, UV 254 nm.
  • the title compound (10 mg, 12%) was obtained.
  • Step 1 (3S, 4R) -4- ( (4- (3- (chloromethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3-methylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro- 2H-pyran-3-ol
  • Step 4 4-isopropyl-2, 3-dimethyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline
  • Step 5 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropyl-2, 3-dimethylquinoline
  • Step 6 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-2, 3-dimethylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (60 mg, 61%) was prepared in a manner similar to Example 1 step 4 from 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropyl-2, 3-dimethylquinoline and (3S, 4R) -4-aminotetrahydro-2H-pyran-3-ol.
  • Step 4 4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline
  • Step 5 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinoline
  • Step 6 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 methyl 6-chloro-4-hydroxy-5-methylquinoline-2-carboxylate
  • Step 5 6-chloro-5-methyl-4- (prop-1-en-2-yl) quinoline
  • Step 7 4-isopropyl-5-methyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline
  • Step 8 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropyl-5-methylquinoline
  • Step 9 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-5-methylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropyl-2-methylquinoline
  • Step 2 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-2-methylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro- 2H-pyran-3-ol
  • Example 1 step 4 The title compound (25 mg, 11%) was prepared in a manner similar to that in Example 1 step 4 from 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropyl-2-methylquinoline and (3S, 4R) -4-aminotetrahydro-2H-pyran-3-ol.
  • Example 12 1- ( (6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) pyrrolidin-2-one
  • Step 1 (6-chloro-4-isopropylquinolin-3-yl) methanol
  • Step 2 (6-chloro-4-isopropylquinolin-3-yl) methyl methanesulfonate
  • Step 3 1- ( (6-chloro-4-isopropylquinolin-3-yl) methyl) pyrrolidin-2-one
  • Step 4 1- ( (4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-3-yl) methyl) pyrrolidin-2-one
  • Step 5 1- ( (6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) pyrrolidin-2-one
  • Step 6 1- ( (6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) pyrrolidin-2-one
  • Example 13 4- ( (6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) morpholin-3-one
  • Step 1 4- ( (6-chloro-4-isopropylquinolin-3-yl) methyl) morpholin-3-one
  • Step 2 4- ( (4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-3-yl) methyl) morpholin-3-one
  • Step 3 4- ( (6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) morpholin-3-one
  • Step 4 4- ( (6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) morpholin-3-one
  • Example 1 step 4 The title compound (25 mg, 10%) was prepared in a manner similar to that in Example 1 step 4 from 4- ( (6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) morpholin-3-one.
  • Step 1 ethyl 6-chloro-2-methyl-4-oxo-1, 4-dihydroquinoline-3-carboxylate
  • Step 2 ethyl 4-bromo-6-chloro-2-methylquinoline-3-carboxylate
  • Step 3 ethyl 6-chloro-4-isopropyl-2-methylquinoline-3-carboxylate
  • Step 4 ethyl 4-isopropyl-2-methyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3- carboxylate
  • Step 5 ethyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropyl-2-methylquinoline-3-carboxylate
  • Step 6 ethyl 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4- isopropyl-2-methylquinoline-3-carboxylate
  • Step 7 (3S, 4R) -4- ( (5-fluoro-4- (3- (hydroxymethyl) -4-isopropyl-2-methylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 16 1- ( (6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) azetidin-3-ol
  • Example 17 can also be obtained by the following steps:
  • Step 1 ethyl 6-chloro-4-isopropylquinoline-3-carboxylate
  • Step 2 ethyl 4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3-carboxylate
  • Step 3 ethyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 4 ethyl 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4- isopropylquinoline-3-carboxylate
  • Step 5 (3S, 4R) -4- ( (5-fluoro-4- (3- (hydroxymethyl) -4-isopropylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 6 (3S, 4R) -4- ( (4- (3- (chloromethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 7 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3- (morpholinomethyl) quinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 28 (3S, 4R) -4- ( (4- (3- ( (cyclohexylamino) methyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (9.5 mg, 16%) was prepared in a manner similar to that in Example 11 step 1 from (3S, 4R) -4- ( (4- (3- (chloromethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and (S) - (tetrahydrofuran-3-yl) methanamine.
  • Example 36 (3S, 4R) -4- ( (4- (3- ( (7-oxa-4-azaspiro [2.5] octan-4-yl) methyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 (3S, 4R) -4- ( (4- (3- (azidomethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 (3S, 4R) -4- ( (4- (3- (aminomethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 39 and Example 40 (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3- ( ( ( (S) -tetrahydrofuran-3-yl) amino) methyl) quinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3- ( ( (R) -tetrahydrofuran-3-yl) amino) methyl) quinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3- ( ( ( (R) -tetrahydrofuran-3-yl) amino) methyl) quinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro
  • Example 39 and Example 40 were separated by chiral HPLC to give (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3- ( ( ( (S) -tetrahydrofuran-3-yl) amino) methyl) quinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and (3S, 4R) -4- ( (5-fluoro-4- (4-isopropyl-3- ( ( ( (R) -tetrahydrofuran-3-yl) amino) methyl) quinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol.
  • Example 41 and Example 42 (3S, 4R) -4- ( (5-fluoro-4- (3- ( (S) -1-hydroxyethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and (3S, 4R) -4- ( (5-fluoro-4- (3- ( (R) -1-hydroxyethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4- isopropylquinoline-3-carbaldehyde
  • Step 2 (3S, 4R) -4- ( (5-fluoro-4- (3- ( (S) -1-hydroxyethyl) -4-isopropylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol and (3S, 4R) -4- ( (5-fluoro-4- (3- ( (R) -1-hydroxyethyl) -4- isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 59 was separated by chiral separation on Chiral-HPLC.
  • Mobile phase: Hexane: EtOH (containing 0.1%diethylamine) 9: 1, 1 mL/min in 18 min.
  • Example 47 and Example 48 (3S, 4R) -4- ( (5-fluoro-4- (3- ( (S) -1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and (3S, 4R) -4- ( (5-fluoro-4- (3- ( (R) -1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and
  • Step 3 1- (6-chloro-4-isopropylquinolin-3-yl) ethan-1-one
  • Step 4 1- (6-chloro-4-isopropylquinolin-3-yl) ethan-1-ol
  • Step 5 6-chloro-3- (1-chloroethyl) -4-isopropylquinoline
  • Step 6 6-chloro-3- (1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinoline
  • Step 7 3- (1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2- dioxaborolan-2-yl) quinoline
  • Step 8 6- (2-chloro-5-fluoropyrimidin-4-yl) -3- (1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4- isopropylquinoline
  • Step 9 (3S, 4R) -4- ( (5-fluoro-4- (3- ( (S) -1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinolin-6- yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and (3S, 4R) -4- ( (5-fluoro-4- (3- ( (R) -1- ( (R) -3- fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and
  • Example 47 was prepared in a manner similar to Example 1 step 4 from 6- (2-chloro-5-fluoropyrimidin-4-yl) -3- (1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinoline.
  • Example 47 and Example 48 were separated on chiral-HPLC to give (3S, 4R) -4- ( (5-fluoro-4- (3- ( (S) -1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (5-fluoro-4- (3- ( (R) -1- ( (R) -3-fluoropyrrolidin-1-yl) ethyl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol.
  • Example 47 (10 mg, 27%) 1 H-NMR (400 MHz, DMSO-d6) ⁇ 9.13-8.87 (m, 2H) , 8.52-8.48 (m, 1H) , 8.30-8.25 (m, 1H) , 8.16-8.09 (m, 1H) , 7.30-7.24 (m, 1H) , 5.32-5.09 (m, 1H) , 5.00-4.96 (m, 1H) , 4.16-4.12 (m, 1H) , 3.88-3.84 (m, 4H) , 3.76-3.45 (m, 2H) , 3.07-3.03 (m, 1H) , 2.97-2.92 (m, 1H) , 2.62-2.57 (m, 2H) , 2.46-2.37 (m, 2H) , 2.16-2.04 (m, 2H) , 1.89-1.84 (m, 1H) , 1.60-1.55 (m, 6H) , 1.45-1.41 (m,
  • Example 47 (11 mg, 29%) 1 H-NMR (400 MHz, DMSO-d6) ⁇ 9.17-9.12 (m, 2H) , 8.67-8.10 (m, 3H) , 7.45-7.18 (m, 1H) , 5.42-4.90 (m, 2H) , 4.40-3.49 (m, 7H) , 3.07-3.03 (m, 2H) , 2.76-2.47 (m, 3H) , 2.38-2.14 (m, 2H) , 2.08-2.03 (m, 2H) , 1.73-1.52 (m, 6H) , 1.48-1.43 (m, 3H) .
  • the title compound (11 mg, 41%) was prepared in a manner similar to that in Example 11 step 1 from (3S, 4R) -4- ( (4- (3- (chloromethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol and (1R, 4R) -2-oxa-5-azabicyclo [2.2.1] heptane hydrochloride.
  • Step 1 1- (6-chloro-4-isopropylquinolin-3-yl) cyclopentan-1-ol
  • Step 2 1- (4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-3-yl) cyclopentan-1- ol
  • This compound can also be obtained by the following step:
  • Step 3 1- (6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinolin-3-yl) cyclopentan-1-ol
  • This compound can also be obtained by the following step:
  • Step 4 (3S, 4R) -4- ( (5-fluoro-4- (3- (1-hydroxycyclopentyl) -4-isopropylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (5 mg, 61%) was prepared in a manner similar to Example 1 step 4 from 1- (6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinolin-3-yl) cyclopentan-1-ol and (3S, 4R) -4-aminotetrahydro-2H-pyran-3-ol hydrochloride.
  • This compound can also be obtained by the following step:
  • Step 1 diethyl 2- ( ( (4-chloro-2-fluorophenyl) amino) methylene) malonate
  • Step 2 ethyl 6-chloro-8-fluoro-4-hydroxyquinoline-3-carboxylate
  • Step 3 ethyl 4-bromo-6-chloro-8-fluoroquinoline-3-carboxylate
  • Step 4 ethyl 6-chloro-8-fluoro-4-isopropylquinoline-3-carboxylate
  • Step 5 ethyl 8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3- carboxylate
  • Step 6 ethyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -8-fluoro-4-isopropylquinoline-3-carboxylate
  • the title compound (420 mg, 45%) was prepared in a manner similar to Example 1 step 3 from ethyl 8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3-carboxylate and 2, 4-dichloro-5-fluoropyrimidine.
  • Step 7 ethyl 8-fluoro-6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin- 4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 8 (3S, 4R) -4- ( (5-fluoro-4- (8-fluoro-3- (hydroxymethyl) -4-isopropylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 (3S, 4R) -4- ( (4- (3- (chloromethyl) -8-fluoro-4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 (3S, 4R) -4- ( (4- (3- ( ( (3, 3-difluorocyclobutyl) amino) methyl) -8-fluoro-4-isopropylquinolin-6- yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (14 mg, 61%) was prepared in a manner similar to that in Example 11 step 1 from (3S, 4R) -4- ( (4- (3- (chloromethyl) -8-fluoro-4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol and (R) -tetrahydro-2H-pyran-3-amine hydrochloride.
  • Example 53 can also be obtained by the following steps:
  • Step 1 diethyl 2- ( ( (4-chloro-2-fluorophenyl) amino) methylene) malonate
  • Step 2 ethyl 6-chloro-8-fluoro-4-hydroxyquinoline-3-carboxylate
  • Step 3 ethyl 4-bromo-6-chloro-8-fluoroquinoline-3-carboxylate
  • Step 4 ethyl 6-chloro-8-fluoro-4-isopropylquinoline-3-carboxylate
  • Step 5 ethyl 8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3- carboxylate
  • Step 6 ethyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -8-fluoro-4-isopropylquinoline-3-carboxylate
  • Step 7 ethyl 8-fluoro-6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin- 4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 8 (3S, 4R) -4- ( (5-fluoro-4- (8-fluoro-3- (hydroxymethyl) -4-isopropylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 9 (3S, 4R) -4- ( (4- (3- (chloromethyl) -8-fluoro-4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 10 (3S, 4R) -4- ( (5-fluoro-4- (8-fluoro-4-isopropyl-3- ( ( ( (R) -tetrahydro-2H-pyran-3- yl) amino) methyl) quinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 55 and Example 56 (3S, 4R) -4- ( (4- (3- ( (S) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (4- (3- ( (R) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (4- (3- ( (R) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 (3S, 4R) -4- ( (4- (3- (1-azidoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 (3S, 4R) -4- ( (4- (3- ( (S) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (4- (3- ( (R) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5- fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 55 was prepared in a manner similar to that in Example 38 step 2 from (3S, 4R) -4- ( (4- (3- (1-azidoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol.
  • Example 55 and Example 56 were separated by chiral-HPLC to give (3S, 4R) -4- ( (4- (3- ( (S) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol & (3S, 4R) -4- ( (4- (3- ( (R) -1-aminoethyl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol.
  • LC-MS (M+H) + 426.1. Chi
  • LC-MS (M+H) + 426.1. Chiral HPLC
  • Example 60 (1R, 3R, 5S) -9- ( (6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinolin-3-yl) methyl) -9-azabicyclo [3.3.1] nonan-3-ol
  • Step 2 2- (6-chloro-8-fluoro-4-isopropylquinolin-3-yl) propan-2-ol
  • Step 3 2- (8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-3-yl) propan- 2-ol
  • Step 6 (3S, 4R) -4- ( (5-fluoro-4- ( (4-methoxybenzyl) oxy) pyrimidin-2-yl) amino) tetrahydro-2H-pyran- 3-yl acetate
  • Step 7 (3S, 4R) -4- ( (5-fluoro-4-hydroxypyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-yl acetate
  • Step 8 (3S, 4R) -4- ( (4-chloro-5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-yl acetate
  • Step 9 (3S, 4R) -4- ( (5-fluoro-4- (8-fluoro-3- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6- yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (11 mg, 20%) was prepared in a manner similar to Example 1 step 3 from 2- (8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-3-yl) propan-2-ol and (3S, 4R) -4- ( (4-chloro-5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-yl acetate.
  • Example 70 (3S, 4R) -4- ( (4- (7-chloro-3- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6-yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 diethyl 2- ( ( (3-chloro-4-methoxyphenyl) amino) methylene) malonate
  • Step 2 ethyl 7-chloro-4-hydroxy-6-methoxyquinoline-3-carboxylate
  • Step 3 ethyl 4, 7-dichloro-6-methoxyquinoline-3-carboxylate
  • Step 4 ethyl 7-chloro-4-isopropyl-6-methoxyquinoline-3-carboxylate
  • reaction mixture was stirred at 50 °C for 3 h before cooled to room temperature and diluted with ethyl acetate (50 mL) . The mixture was washed with brine, dried over sodium sulfate, filtered and concentrated under reduce pressure. The residue was purified by silica gel column chromatography, eluting with ethyl acetate in petroleum ether (50%, v/v) to give the title compound (1.4 g, 69%) .
  • LC-MS (M+H) + 308.3.
  • Step 5 ethyl 7-chloro-6-hydroxy-4-isopropylquinoline-3-carboxylate
  • Step 6 ethyl 7-chloro-4-isopropyl-6- ( ( (trifluoromethyl) sulfonyl) oxy) quinoline-3-carboxylate
  • Step 7 ethyl 7-chloro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3- carboxylate
  • Step 8 ethyl 7-chloro-6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 9 ethyl 7-chloro-6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4- yl) amino) pyrimidin-4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 10 (3S, 4R) -4- ( (4- (7-chloro-3- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6-yl) -5- fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 diethyl 2- ( ( (4-chloro-3-fluorophenyl) amino) methylene) malonate
  • Step 2 ethyl 6-chloro-7-fluoro-4-hydroxyquinoline-3-carboxylate
  • Step 3 ethyl 4, 6-dichloro-7-fluoroquinoline-3-carboxylate and ethyl 4, 6-dichloro-5- fluoroquinoline-3-carboxylate
  • Step 4 ethyl 6-chloro-7-fluoro-4-isopropylquinoline-3-carboxylate
  • Step 5 ethyl 7-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-3- carboxylate
  • Step 6 ethyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -7-fluoro-4-isopropylquinoline-3-carboxylate
  • Step 7 ethyl 7-fluoro-6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin- 4-yl) -4-isopropylquinoline-3-carboxylate
  • Step 8 (3S, 4R) -4- ( (5-fluoro-4- (7-fluoro-3- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6- yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 2- (6- (2, 5-dichloropyrimidin-4-yl) -8-fluoro-4-isopropylquinolin-3-yl) propan-2-ol
  • Step 2 (3S, 4R) -4- ( (5-chloro-4- (8-fluoro-3- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6- yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Example 117 can be obtained by the following procedures:
  • Step 1 diethyl 2- ( ( (4-chloro-2-fluorophenyl) amino) methylene) malonate
  • Step 2 ethyl 6-chloro-8-fluoro-4-hydroxyquinoline-3-carboxylate
  • Step 3 ethyl 4-bromo-6-chloro-8-fluoroquinoline-3-carboxylate
  • Step 5 2- (6-chloro-8-fluoro-4-isopropylquinolin-3-yl) propan-2-ol
  • Step 6 2- (8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-3-yl) propan- 2-ol
  • Step 7 2- (6- (2, 5-dichloropyrimidin-4-yl) -8-fluoro-4-isopropylquinolin-3-yl) propan-2-ol
  • Step 8 (3S, 4R) -4- ( (5-chloro-4- (8-fluoro-3- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6- yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 ethyl 6-chloro-4-hydroxy-8-iodo-5-methylquinoline-3-carboxylate
  • Step 4 ethyl 4, 6-dichloro-5-methylquinoline-3-carboxylate
  • Step 5 ethyl 6-chloro-4-isopropyl-5-methylquinoline-3-carboxylate
  • Zinc chloride solution in tetrahydrofuran (1N, 6.92 mL, 6.92 mmol) was added to isopropylmagnesium chloride solution in tetrahydrofuran (6.92 mL, 1N, 6.92 mmol) at 0 °C and the reaction mixture was heated to 50 °C under nitrogen for 1 h before cooled to 0 °C.
  • Step 7 (6-chloro-4-isopropyl-5-methylquinolin-3-yl) (1H-imidazol-1-yl) methanone
  • Step 8 (6-chloro-4-isopropyl-5-methylquinolin-3-yl) methanol
  • Step 9 3- ( ( (tert-butyldimethylsilyl) oxy) methyl) -6-chloro-4-isopropyl-5-methylquinoline
  • Step 10 3- ( ( (tert-butyldimethylsilyl) oxy) methyl) -6- (2-chloro-5-fluoropyrimidin-4-yl) -4- isopropyl-5-methylquinoline
  • Step 11 (3S, 4R) -4- ( (4- (3- ( ( (tert-butyldimethylsilyl) oxy) methyl) -4-isopropyl-5-methylquinolin-6- yl) -5-fluoropyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 12 (3S, 4R) -4- ( (5-fluoro-4- (3- (hydroxymethyl) -4-isopropyl-5-methylquinolin-6-yl) pyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 (3S, 4R) -4- ( (4- (3- (chloromethyl) -4-isopropyl-5-methylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 (3S, 4R) -4- ( (4- (3- (aminomethyl) -4-isopropyl-5-methylquinolin-6-yl) -5-fluoropyrimidin-2- yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 methyl 6-chloro-4-oxo-1, 4-dihydroquinoline-2-carboxylate
  • Step 4 methyl 6-chloro-4- (prop-1-en-2-yl) quinoline-2-carboxylate
  • Step 5 methyl 4- (prop-1-en-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-2-carboxylate
  • Step 6 methyl 4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline-2-carboxylate
  • Step 7 methyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinoline-2-carboxylate
  • Step 8 methyl 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinoline-2-carboxylate
  • Step 9 (3S, 4R) -4- ( (5-fluoro-4- (2- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 1 ethyl 2- ( (2-carbamoyl-4-chlorophenyl) amino) -2-oxoacetate
  • Step 2 methyl 6-chloro-4-oxo-1, 4-dihydroquinazoline-2-carboxylate
  • Step 4 methyl 6-chloro-4- (prop-1-en-2-yl) quinazoline-2-carboxylate
  • Step 5 methyl 4- (prop-1-en-2-yl) -6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinazoline-2-carboxylate
  • Step 6 methyl 4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinazoline-2-carboxylate
  • Step 7 methyl 6- (2-chloro-5-fluoropyrimidin-4-yl) -4-isopropylquinazoline-2-carboxylate
  • Step 8 methyl 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinazoline-2-carboxylate
  • Step 9 (3S, 4R) -4- ( (5-fluoro-4- (2- (2-hydroxypropan-2-yl) -4-isopropylquinazolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (10 mg, 10 %) was prepared in a manner similar to Example 206 step 9 from methyl 6- (5-fluoro-2- ( ( (3S, 4R) -3-hydroxytetrahydro-2H-pyran-4-yl) amino) pyrimidin-4-yl) -4-isopropylquinazoline-2-carboxylate and methylmagnesium iodide.
  • Step 2 methyl 6-chloro-8-fluoro-4-oxo-1, 4-dihydroquinoline-2-carboxylate
  • Step 3 methyl 4-bromo-6-chloro-8-fluoroquinoline-2-carboxylate
  • Step 4 methyl 6-chloro-8-fluoro-4-isopropylquinoline-2-carboxylate
  • Step 5 2- (6-chloro-8-fluoro-4-isopropylquinolin-2-yl) propan-2-ol
  • Step 6 2- (8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinolin-2-yl) propan-2-ol
  • Step 7 2- (6- (2, 5-dichloropyrimidin-4-yl) -8-fluoro-4-isopropylquinolin-2-yl) propan-2-ol
  • Step 8 (3S, 4R) -4- ( (5-chloro-4- (8-fluoro-2- (2-hydroxypropan-2-yl) -4-isopropylquinolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • Step 2 ethyl 6-chloro-8-fluoro-4-hydroxyquinazoline-2-carboxylate
  • Step 3 ethyl 4-bromo-6-chloro-8-fluoroquinazoline-2-carboxylate
  • Step 4 ethyl 6-chloro-8-fluoro-4-isopropylquinazoline-2-carboxylate
  • Step 5 2- (6-chloro-8-fluoro-4-isopropylquinazolin-2-yl) propan-2-ol
  • Step 6 2- (8-fluoro-4-isopropyl-6- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinazolin-2-yl) propan-2-ol
  • Step 7 2- (6- (2, 5-dichloropyrimidin-4-yl) -8-fluoro-4-isopropylquinazolin-2-yl) propan-2-ol
  • Step 8 (3S, 4R) -4- ( (5-chloro-4- (8-fluoro-2- (2-hydroxypropan-2-yl) -4-isopropylquinazolin-6-yl) pyrimidin-2-yl) amino) tetrahydro-2H-pyran-3-ol
  • the title compound (28 mg, 41%) was prepared in a manner similar to that in Example 4 step 6 from 2- (6- (2, 5-dichloropyrimidin-4-yl) -8-fluoro-4-isopropylquinazolin-2-yl) propan-2-ol and (3S, 4R) -4-aminooxan-3-ol hydrochloride.
  • TR-FRET time-resolved fluorescence-resonance energy transfer
  • the assay was carried out in 384-well low volume black plates in a reaction mixture containing CDK4/Cyclin D1 or CDK6/Cyclin D3, 1 mM ATP, 0.15 ⁇ M Rb (Ser780) -biotin substrate and 0-10 ⁇ M compound in buffer containing 50 mM HEPES pH7.0, 0.02%NaN3, 0.01%BSA, 0.1mM Orthovanadate, 50 mM MgCl2, 1 mM DTT and 0.005%Tween-20.
  • the kinase was incubated with compound for 60 minutes at room temperature and the reaction was initiated by the addition of ATP and Rb (Ser780) -biotin substrate.
  • stop/detection solution After reaction at room temperature for 120 minutes, an equal volume of stop/detection solution was added according to the manufacture’s instruction (Cisbio Bioassays) .
  • the stop/detection solution contained Streptavidin-XL665 and Anti-pRb (Ser780) mAb-Eu Cryptate in Detection buffer (Cisbio Bioassays) . Plates were incubated at room temperature for 60 minutes, and the TR-FRET signals (ex337nm, em665nm/620nm) were recorded on a PHERAstar FSX plate reader (BMG Labtech) .
  • the inhibition percentage of CDK4/Cyclin D1 or CDK6/Cyclin D3 kinase activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 665 nm to that at 620 nm.
  • the IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Dotmatics.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/CN2023/091483 2022-04-29 2023-04-28 Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors Ceased WO2023208173A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA3256792A CA3256792A1 (en) 2022-04-29 2023-04-28 Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors
EP23795605.7A EP4514791A4 (en) 2022-04-29 2023-04-28 6-(PYRIMIDIN-4-YL) QUINOLEIC SUBSTITUTE COMPOUNDS USED AS CYCLINE-DEPENDENT KINASE INHIBITORS
AU2023260284A AU2023260284A1 (en) 2022-04-29 2023-04-28 Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors
CN202380036165.1A CN119095840A (zh) 2022-04-29 2023-04-28 作为周期蛋白依赖性激酶抑制剂的经取代的6-(嘧啶-4-基)喹啉化合物
IL316556A IL316556A (en) 2022-04-29 2023-04-28 6-(Pyrimidine-4-yl)quinoline compounds are being developed as cyclin-dependent kinase inhibitors.
JP2024563509A JP2025516213A (ja) 2022-04-29 2023-04-28 サイクリン依存性キナーゼ阻害剤としての置換６－（ピリミジン－４－イル）キノリン化合物
KR1020247039643A KR20250004890A (ko) 2022-04-29 2023-04-28 사이클린 의존성 키나제 저해제로서의 치환된 6-(피리미딘-4-일)퀴놀린 화합물
CN202510407101.9A CN120441555A (zh) 2022-04-29 2023-04-28 作为周期蛋白依赖性激酶抑制剂的经取代的6-(嘧啶-4-基)喹啉化合物
US18/623,847 US20240300937A1 (en) 2022-04-29 2024-04-01 Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors
MX2024013266A MX2024013266A (es) 2022-04-29 2024-10-25 Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
CONC2024/0014595A CO2024014595A2 (es) 2022-04-29 2024-10-25 Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2022090344 2022-04-29
CNPCT/CN2022/090344 2022-04-29
CNPCT/CN2022/105964 2022-07-15
CN2022105964 2022-07-15
CNPCT/CN2023/085071 2023-03-30
CN2023085071 2023-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/623,847 Continuation US20240300937A1 (en) 2022-04-29 2024-04-01 Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors

Publications (1)

Publication Number Publication Date
WO2023208173A1 true WO2023208173A1 (en) 2023-11-02

Family

ID=88517887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/091483 Ceased WO2023208173A1 (en) 2022-04-29 2023-04-28 Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors

Country Status (14)

Country Link
US (1) US20240300937A1 (enExample)
EP (1) EP4514791A4 (enExample)
JP (1) JP2025516213A (enExample)
KR (1) KR20250004890A (enExample)
CN (2) CN119095840A (enExample)
AR (1) AR129185A1 (enExample)
AU (1) AU2023260284A1 (enExample)
CA (1) CA3256792A1 (enExample)
CL (1) CL2024003269A1 (enExample)
CO (1) CO2024014595A2 (enExample)
IL (1) IL316556A (enExample)
MX (1) MX2024013266A (enExample)
TW (1) TW202400585A (enExample)
WO (1) WO2023208173A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025078995A1 (en) * 2023-10-11 2025-04-17 Beigene Switzerland Gmbh Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors
US12338248B2 (en) 2023-07-21 2025-06-24 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US20090298830A1 (en) * 2006-01-30 2009-12-03 Exelixis, Inc. 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118286225A (zh) * 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
WO2022149057A1 (en) * 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
US20090298830A1 (en) * 2006-01-30 2009-12-03 Exelixis, Inc. 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4514791A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338248B2 (en) 2023-07-21 2025-06-24 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025078995A1 (en) * 2023-10-11 2025-04-17 Beigene Switzerland Gmbh Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
AR129185A1 (es) 2024-07-24
CN120441555A (zh) 2025-08-08
IL316556A (en) 2024-12-01
MX2024013266A (es) 2024-12-06
AU2023260284A1 (en) 2024-11-14
KR20250004890A (ko) 2025-01-08
EP4514791A4 (en) 2026-03-11
EP4514791A1 (en) 2025-03-05
CO2024014595A2 (es) 2024-12-30
CL2024003269A1 (es) 2025-03-07
CN119095840A (zh) 2024-12-06
US20240300937A1 (en) 2024-09-12
JP2025516213A (ja) 2025-05-27
CA3256792A1 (en) 2023-11-02
TW202400585A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
EP4291193A1 (en) Egfr degraders and methods of use
WO2022068849A1 (en) Bifunctional compounds for degradation of egfr and related methods of use
WO2021013083A1 (en) Tricyclic compounds as hpk1 inhibitor and the use thereof
WO2021032148A1 (en) Aminopyrazine compounds as hpk1 inhibitor and the use thereof
WO2023098699A1 (en) Compounds and their uses as cd38 inhibitors
US20240300937A1 (en) Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors
EP4359403A1 (en) (r) -glutarimide crbn ligands and methods of use
WO2023174250A1 (en) 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5
EP4688785A1 (en) 5-amino-6, 8-dihydro-1h-furo [3, 4-d] pyrrolo [3, 2-b] pyridine-2-carboxamide derivatives as mta-cooperative inhibitors of prmt5
EP4615850A1 (en) Compounds for the degradation of egfr kinase
WO2019196803A1 (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
WO2020020097A1 (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
WO2024088323A1 (en) Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors
WO2024230803A1 (en) Isoquinolinone derivatives and 4h-quinolizinone derivatives and pharmarceutical compositions thereof for the treatment of disease
WO2024099402A1 (en) Intermediates and process of compounds for the degradation of egfr kinase
WO2024099400A1 (en) Intermediates and process of compounds for the degradation of egfr kinase
US20250136586A1 (en) Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
WO2025021217A1 (en) Quinoline derivatives and pharmarceutical compositions thereof for the treatment of disease
WO2024245430A1 (en) Compounds for the degradation of egfr kinase
WO2025078995A1 (en) Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors
WO2022227032A1 (en) Egfr degraders and associated methods of use
CN117946077A (zh) 作为周期蛋白依赖性激酶抑制剂的经取代的6-(嘧啶-4-基)喹啉化合物
WO2025201504A1 (en) Kat6 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23795605

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380036165.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/013266

Country of ref document: MX

Ref document number: NC2024/0014595

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 316556

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024563509

Country of ref document: JP

Ref document number: 12024552574

Country of ref document: PH

Ref document number: 815846

Country of ref document: NZ

Ref document number: 2401007115

Country of ref document: TH

Ref document number: AU2023260284

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P2024-02882

Country of ref document: AE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024022251

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2023260284

Country of ref document: AU

Date of ref document: 20230428

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202417091068

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20247039643

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202492809

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11202407536Y

Country of ref document: SG

Ref document number: 2023795605

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023795605

Country of ref document: EP

Effective date: 20241129

WWP Wipo information: published in national office

Ref document number: NC2024/0014595

Country of ref document: CO

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112024022251

Country of ref document: BR

Free format text: - APRESENTAR NOVAS FOLHAS REFERENTES AO RELATORIO DESCRITIVO TRADUZIDO E AO RESUMO DO PEDIDO, ADAPTADAS AOS ARTS. 26 E 40 DA PORTARIA INPI NO14/2024, UMA VEZ QUE O CONTEUDO ENCAMINHADO ENCONTRA-SE FORA DA NORMA (USO DE EXPRESSAO ADICIONAL ANTES DO TITULO); - APRESENTAR NOVAS FOLHAS REFERENTES AO RELATORIO DESCRITIVO TRADUZIDO E AO QUADRO REIVINDICATORIO, ADAPTADAS AO ART. 20 DA PORTARIA/INPI/NO 14/2024, UMA VEZ QUE TODAS AS TABELAS INSERIDAS NOS TEXTOS DEVEM SER IDENTIFICADAS DE FORMA SEQUENCIAL. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO, POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112024022251

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20241025